{"id":43015,"date":"2021-10-19T15:44:03","date_gmt":"2021-10-19T14:44:03","guid":{"rendered":"https:\/\/touchoncology.com\/?post_type=media_gallery&#038;p=43015"},"modified":"2021-10-19T15:44:03","modified_gmt":"2021-10-19T14:44:03","slug":"domenica-lorusso-esmo-2021-relacorilant-in-combination-with-nab-paclitaxel-for-patients-with-recurrent-platinum-resistant-ovarian-cancer","status":"publish","type":"media_gallery","link":"https:\/\/touchoncology.com\/ovarian-cancer\/conference-hub\/domenica-lorusso-esmo-2021-relacorilant-in-combination-with-nab-paclitaxel-for-patients-with-recurrent-platinum-resistant-ovarian-cancer\/","title":{"rendered":"Domenica Lorusso, ESMO 2021: Relacorilant in Combination with Nab-paclitaxel for Patients with Recurrent Platinum-resistant Ovarian Cancer"},"content":{"rendered":"<p>touchONCOLOGY joins <strong>Dr Domenica Lorusso<\/strong> (Rome, Italy), to discuss the improvements in progression-free survival in patients with recurrent platinum-resistant ovarian cancer using relacorilant in combination with nab-paclitaxel. (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03776812\" target=\"_blank\" rel=\"noopener\">NCT03776812<\/a>)<\/p>\n<p><strong>Question<br \/>\n<\/strong>Please summarise the randomized, open-label, phase II study presented at ESMO 2021 exploring progression-free survival in patients with recurrent platinum-resistant ovarian cancer using relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel.<\/p>\n<ul>\n<li>Rationale and aims of the study: 00:30-04:05<\/li>\n<li>Primary endpoints and results: 04:05-06:17<\/li>\n<li>Conclusions and impact on future treatment: 06:17-07:29<\/li>\n<\/ul>\n<p><strong>Disclosures<\/strong>: Domenica Lorusso has no financial or non-financial conflicts of interest to declare in relation to this video.<\/p>\n<p><strong>Support<\/strong>: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.<\/p>\n<p><em>Filmed in coverage of the ESMO 2021 Annual Meeting.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>touchONCOLOGY joins Dr Domenica Lorusso (Rome, Italy), to discuss the improvements in progression-free survival in patients with recurrent platinum-resistant ovarian cancer using relacorilant in combination with nab-paclitaxel. (NCT03776812) Question Please summarise the randomized, open-label, phase II study presented at ESMO 2021 exploring progression-free survival in patients with recurrent platinum-resistant ovarian cancer using relacorilant, a selective [&hellip;]<\/p>\n","protected":false},"featured_media":43016,"template":"","class_list":["post-43015","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-ovarian-cancer","video_categories-esmo-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/43015","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":3,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/43015\/revisions"}],"predecessor-version":[{"id":43019,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/43015\/revisions\/43019"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media\/43016"}],"wp:attachment":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media?parent=43015"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}